.
.
.
Drug Discovery Services
ResolveMass Laboratories Inc. provides advanced Drug Discovery Services tailored for biotechnology companies, pharmaceutical organizations, and academic research teams seeking to accelerate therapeutic innovation. Our scientists support projects from early hit identification through preclinical development using validated workflows, specialized instrumentation, and proven discovery strategies.
Our capabilities include:
- Target validation & assay development
- High-throughput screening & hit discovery
- Lead optimization & medicinal chemistry
- ADME-Tox & pharmacokinetic profiling
- Bioanalytical method development
- Computational modeling & structure-based design
Trusted by Research Leaders
ResolveMass Laboratories partners with early-stage biotech companies, mid-sized pharmaceutical developers, clinical research organizations, and university-based lab groups that require fast, reliable, and data-driven support in early drug discovery. Many of our clients leverage our expertise to fill gaps in assay development, screening capacity, medicinal chemistry resourcing, or analytical instrumentation, enabling them to progress research objectives without delays tied to capital investment or talent acquisition.
To ensure the highest precision in molecular identification, we offer expert high-resolution mass spectrometry (HRMS) analysis to support even the most complex discovery workflows. This makes ResolveMass an ideal strategic partner for teams preparing for preclinical milestones, IND-enabling studies, grant-funded initiatives, and venture-backed R&D programs.
Expertise That Reduces Risk in Early R&D
Our discovery scientists have backgrounds in analytical chemistry, molecular biology, pharmacology, and medicinal chemistry with direct experience in therapeutic development across oncology, CNS disorders, infectious disease, metabolic disease, and rare disease programs. Every project is led by senior specialists who have contributed to funded R&D programs, successful IND filings, and peer-reviewed publications. When unique molecular structures are required for testing, our team provides professional custom synthesis services to meet your specific project specifications.
Comprehensive Drug Discovery Workflow Support
(A) Target Discovery & Validation
We characterize biological targets using biochemical assays, cell-based systems, and computational analysis to confirm mechanistic relevance before full discovery investment. This stage ensures that the target influences disease biology in a measurable and modifiable way. By validating both feasibility and therapeutic potential early, we help reduce development risk and improve downstream decision making.
(B) Assay Development & Screening
After validation, our scientists design and optimize assays that accurately measure compound activity, selectivity, and functional impact. Using high-throughput screening infrastructure, curated compound libraries, and automated workflows, we identify promising hits with reproducible performance across multiple assay platforms. For robust quantification of small molecules, we utilize industry-leading LC-MS analysis techniques to confirm hit viability.
(C) Lead Optimization & Medicinal Chemistry
Once hits are confirmed, we refine chemical structures through medicinal chemistry campaigns aimed at improving potency, target affinity, and pharmacokinetic behavior. Optimization efforts integrate ADME profiling and specialized impurity profiling using LCMS to ensure the highest purity of lead candidates. This iterative approach strengthens molecular viability for preclinical development and future regulatory progression.
(D) ADME-Tox Services
Our ADME-Tox panels include:
- Metabolic stability
- Solubility & permeability
- Plasma protein binding
- Cytotoxicity studies
- hERG & safety pharmacology
To support these critical safety assessments, we provide comprehensive bioanalytical services that deliver the precise data needed for pharmacokinetic evaluations.
Specialized Instrumentation Accelerating Discovery
ResolveMass Laboratories operates analytical and bioanalytical platforms including high-performance GC-MS analysis, HPLC, NMR, automated screening systems, and molecular modeling suites to ensure accuracy, reproducibility, and confidence in discovery pipelines.
Data-Driven Standards for Regulatory-Compatible Research
All studies follow traceable documentation practices, controlled workflows, and quality management systems aligned with regulatory expectations. This includes addressing safety concerns early through validated nitrosamine testing and analysis
as well as rigorous extractables and leachables (E&L) testing to ensure product integrity for future IND submissions.
Why R&D Teams Choose ResolveMass Laboratories
- Scientific leadership with discovery program experience
- Reduced development timelines
- Transparent data delivery & reporting
- Flexible partnership models (FTE, fee-for-service, hybrid)
- Proven success with multi-year research collaborations
Start Your Project with Our Discovery Team
Speak with our scientific project leads to review objectives, timelines, scope, and technical requirements. NDAs available before technical discussion.
Frequently Asked Questions
Drug discovery is the scientific process of identifying new compounds that have the potential to become therapeutic medicines. It involves understanding disease mechanisms, selecting biological targets, and screening molecules that can modulate those targets. The goal is to find safe and effective candidates that can advance toward clinical development.
The four commonly recognized stages of drug discovery include target identification, hit discovery, lead optimization, and preclinical development. These stages move systematically from understanding disease biology to refining compounds for safety and performance. Each step generates data that supports decisions for further advancement into clinical trials.
Typical steps in drug discovery include target selection, assay development, compound screening, hit-to-lead progression, medicinal chemistry optimization, and ADME-Tox evaluation. These steps collectively assess how well a compound interacts with a biological target and whether it exhibits drug-like characteristics. The final outcome is a development candidate suitable for preclinical testing.
Drug discovery strategies can be categorized into approaches such as phenotypic screening, target-based discovery, structure-based design, and computational or virtual screening. Some programs also incorporate fragment-based methods or natural product discovery. Each approach differs in how compounds are identified but ultimately aims to produce viable therapeutic candidates.
Methods used in drug discovery include biochemical and cell-based assays, high-throughput screening, in-silico modeling, structural biology, and medicinal chemistry. Many modern programs combine experimental and computational methods to reduce time and cost. The selected method typically depends on the therapeutic area, target biology, and available data.
A common example of drug discovery is the development of imatinib, a targeted therapy designed to inhibit the BCR-ABL fusion protein in chronic myeloid leukemia. Through target validation, screening, and optimization, imatinib emerged as a molecule that transformed disease outcomes. It illustrates how understanding disease biology can lead to precise therapeutic solutions.
The three pillars of drug discovery are target, molecule, and patient. A validated target ensures biological relevance, a well-optimized molecule provides the pharmacological action, and an aligned patient population ensures therapeutic benefit. Balancing these pillars increases the likelihood of clinical and commercial success.
CONCLUSION
ResolveMass Laboratories delivers reliable and scientifically rigorous Drug Discovery Services that enable biotech, pharma, and academic teams to move promising therapeutics toward clinical development with greater confidence and efficiency.
Reference
- Shareef, U., Altaf, A., Ahmed, M., Akhtar, N., Almuhayawi, M. S., Al Jaouni, S. K., Selim, S., Abdelgawad, M. A., & Nagshabandi, M. K. (2023). A comprehensive review of discovery and development of drugs discovered from 2020–2022. Saudi Pharmaceutical Journal, 32(1), 101913. https://pmc.ncbi.nlm.nih.gov/articles/PMC10777120/
- Darji, P., Patel, J., Patel, B., Khatri, V., Fnu, P. I. J., & Nalla, S. (2024). Comprehensive review on drug discovery and development process. Journal of Chemical Health Risks, 14(3). https://www.jchr.org/index.php/JCHR/article/view/5000
- U.S. Food and Drug Administration. (n.d.). Drug development and review definitions. U.S. Department of Health and Human Services. Retrieved January 8, 2026, from https://www.fda.gov/drugs/investigational-new-drug-ind-application/drug-development-and-review-definitions
- Patel, P., Sharma, V., & Meshram, D. B. (2024). A review on drug design and development. International Journal of Pharmacognosy and Pharmaceutical Research, 6(2), 08–20. https://www.pharmacognosyjournals.com/archives/2024/vol6issue2/PartA/6-2-1-793.pdf